Strong Start: Nussbaum Named to Select NCI Surgeon-Scientist Program Cohort

Headshot of Daniel Nussbaum, MD
Daniel Nussbaum, MD

Daniel Nussbaum, MD, assistant professor, Department of Surgery, Division of Surgical Oncology, is one of 12 young surgeons nationwide to be selected by the National Institutes of Health/National Cancer Institute for the 2023 Early-Stage Surgeon Scientist Program (ESSP).

This pilot program brings together surgeon scientists from across the U.S.; building cohorts that will be trained together for up to three years per cohort.

ESSP participants are funded through either an administrative supplement to the grantee’s NCI-designated Cancer Center Support Grant (P30) (of which Duke Cancer Institute is a recipient) or Comprehensive Partnerships to Advance Cancer Health Equity (CPACHE; U54) to one of the institutions serving underserved health disparity populations and underrepresented students.

A Strong Start

Nussbaum is also one of four faculty members at Duke to have been selected to receive a 2023 Physician-Scientist “Strong Start” award.

According to the Duke University School of Medicine, the awards program, funded with a gift from the Nanaline H. Duke Fund, supports promising early-career physician-scientists at Duke as they develop independent research programs. Each recipient will receive $75,000 annually for three years to support their research programs.

The Strong Start program is administered by the School of Medicine’s Office for Physician-Scientist Development (OPSD) and integrates with other physician-scientist development programs including the Medical Scientist Training Program (MD-PhD students) and the Lefkowitz Society (clinical residents and fellows). 

Nussbaum, who's a member of the Lefkowitz Society, has been an assistant professor of Surgery and a Duke Cancer Institute member since 2021. Previous to Duke, he completed his Surgical Oncology Fellowship at Memorial Sloan-Kettering Cancer Center (2019 - 2021) and a General Surgery Residency at Duke (2011-2019). He earned his MD from the University of Southern California in 2011.

The "Strong Start" award will support his research project: "Deciphering Mechanisms of Hepatic Immunity Governing Pancreatic Cancer Liver Metastasis." Nussbaum will be working under the joint mentorship of Peter Allen, MD, and H. Kim Lyerly, MD, and with collaborators/co-mentors Erika Crosby, PhD, Zachary Hartman, PhD, Joshua Snyder, PhD, and Christopher Counter, PhD.

A Silent Killer

Even in its earliest stages, pancreatic cancer remains "an essentially incurable disease," explains Nussbaum. Among patients who undergo potentially “curative” surgery, greater than 95% will nonetheless die within 10 years of diagnosis. The vast majority (~80%) of these patients develop liver metastases — often within one year of surgery — and these metastases dictate survival outcomes.

“While we can treat a single tumor with surgery and chemotherapy, which currently represents our standard-of-care approach, it is overwhelmingly difficult to truly cure patients with these conventional therapies alone," says Nussbaum. "The challenge lies in eradicating pancreatic cancer cells that have already spread to the liver by the time the primary tumor in the pancreas is discovered. Because these metastatic cells can't be picked up with radiographic imaging — what we call "occult" cancer cells even patients who present at an early stage face a very high risk of postoperative recurrence. Due to the microscopic nature of occult metastases, our fundamental understanding of the mechanisms behind this disease state has lagged. In order to offer truly curative treatment for patients with “localized” pancreatic cancer, it's critical that we find ways to target those pancreatic cancer cells that have evaded detection."

"The Strong Start Award will provide a crucial springboard for my career and support a novel line of investigation with the potential to foundationally shape our understanding of occult metastatic disease," says Nussbaum, who will focus on related research with the NCI Early-Stage Surgeon Scientist Program (ESSP) cohort.

Nussbaum is also receiving research support for his project  — "Comprehensive Profiling of Hepatic Immune Populations to Target Occult Liver Metastasis in Pancreatic Cancer." This grant is supported by the Hopper-Belmont Foundation (2023 - 2024).

"My long-term goal as a pancreatic cancer surgeon-scientist is to develop therapeutic strategies, which build on this research, in order to improve cure rates for my patients," says Nussbaum.

Related News

Three images of groups of people posing
THE GRADUATE Monica Bodd, MD, MTS, at her MD Graduation with Associate Dean for Student Affairs Aimee Chung, MD, her advisory dean (left); her primary Duke Surgery mentor DCI head & neck surgical oncologist Dan Rocke, MD (top right) and clinic staff; and with her proud parents on match day (bottom right).

Lessons from Duke: Centering the Patient Experience & a Role for Theology

Monica Bodd thinks a lot about the patient experience and how to make it better — both through research and clinical practice. While earning her MD and her Masters of Theological Studies degrees at Duke, she learned from some of the best, including Thomas LeBlanc, MD, MA, MHS, Dan Rocke, MD, JD, and Walter Lee, MD, MHS, from Duke Cancer Institute, and from the Duke Divinity School, Warren Kinghorn MD, ThD, Sarah Barton OT, ThD,Susan Eastman, MDiv, PhD, and Kate Bowler, PhD. Patient experience research in oncology is an investigation of common issues faced by people with cancer, including symptom burden, quality of life, and psychological distress, as well as how patients understand their prognosis and make decisions about their treatment through the various stages of their disease. “The way I explain it to my friends or to my family, it’s about asking patients how they live and work through their diagnoses on a day-to-day basis, centering their perspective over the perspective of a medical record or a diagnosis or a doctor's words,” said Bodd. “There are validated and quantitative aspects to it, but it’s more about what we wouldn't necessarily capture with our big data and metrics… I believe it’s the redeeming hope for a lot of medicine.” As Bodd was leaving Duke to begin her residency in Otolaryngology-Head & Neck Surgery at Stanford Medicine this past spring, she spoke with DCI about some of the unique projects she got to work on and co-lead as a medical student and theology student — and the wisdom and practices she’s carrying forward in her medical career from both disciplines.

Headshot of Terry McDonnell

McDonnell Joins DUHS as Chief Nurse Executive

Terry McDonnell,DNP, ACNP-BC,has been named chief nurse executive for Duke University Health System. She will work closely with chief nursing officers and other system leaders to increase a sense of purpose among frontline clinical teams and ensure patients receive world-class care. McDonnell has a doctorate in nursing and is an Acute Care-Certified Nurse Practitioner who specializes in treating patients with gastrointestinal cancers. Most recently, she served as the vice president of clinical operations and chief nursing officer of the Fred Hutchinson Cancer Center in Seattle, Wash., where she was responsible for the oversight of clinical and professional staff to ensure they delivered patient-centric care. CONTINUE READING